

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta162lcon

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family searching
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28 JUN 19 CAS REGISTRY includes selected substances from web-based collections
NEWS 29 JUN 25 CA/CAplus and USPAT databases updated with IPC reclassification data

• 10/568,655 07/27/2008

NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

| | |
|------------|---|
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS IPC8 | For general information regarding STN implementation of IPC 8 |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:07:01 ON 27 JUL 2008

=> FILE REG
COST IN U.S. DOLLARS . SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 13:07:43 ON 27 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2008 HIGHEST RN 1036147-29-1
DICTIONARY FILE UPDATES: 25 JUL 2008 HIGHEST RN 1036147-29-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

>

Uploading C:\Program Files\Stnexp\Queries\GM.str



chain nodes :

25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
48 49 50

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24

chain bonds :

1-43 2-44 3-45 4-42 5-26 6-48 7-25 8-34 9-33 10-32 11-31 12-30 13-35
14-25 15-28 16-29 17-27 18-36 19-39 20-40 21-41 22-25 23-37 24-38 25-26
44-49 45-50

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

1-2 1-6 1-43 2-3 2-44 3-4 3-45 4-5 4-42 5-6

exact bonds :

5-26 6-48 7-25 8-34 9-33 10-32 11-31 12-30 13-35 14-25 15-28 16-29
17-27 18-36 19-39 20-40 21-41 22-25 23-37 24-38 25-26 44-49 45-50

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18 14-15 15-16 16-17 17-18 19-20
19-24 20-21 21-22 22-23 23-24

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 48:CLASS 49:CLASS 50:CLASS

10/568,655

07/27/2008

=> S L1 FULL
FULL SEARCH INITIATED 13:08:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 115 TO ITERATE

100.0% PROCESSED 115 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.01

L2 21 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
178.36 178.57

FILE 'CAPLUS' ENTERED AT 13:08:35 ON 27 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 25 Jul 2008 (20080725/ED).

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> S L2
L3 35 L2

=> D L3 IBIB ABS HITSTR 1-35

L3 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:459952 CAPLUS
DOCUMENT NUMBER: 149:47117
TITLE: Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells
AUTHOR(S): Ross, Meredith F.; Prime, Tracy A.; Abakumova, Irina; James, Andrew M.; Porteous, Carolyn M.; Smith, Robin A. J.; Murphy, Michael P.
CORPORATE SOURCE: Wellcome Trust/MRC Building, Medical Research Council Dunn Human Nutrition Unit, Cambridge, CB2 0XY, UK
SOURCE: Biochemical Journal (2008), 411(3), 633-645

CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Mitochondria-targeted mols. comprising the lipophilic TPP (triphenylphosphonium) cation covalently linked to a hydrophobic bioactive moiety are used to modify and probe mitochondria in cells and *in vivo*. However, it is unclear how hydrophobicity affects the rate and extent of their uptake into mitochondria within cells, making it difficult to interpret expts. because their intracellular concentration in different compartments is uncertain. To address this issue, we compared the uptake into both isolated mitochondria and mitochondria within cells of two hydrophobic TPP derivs., [³H]MitoQ (mitoquinone) and [³H]DecylTPP, with the more hydrophilic TPP cation [³H]TPMP (methyltriphenylphosphonium). Uptake of MitoQ by mitochondria and cells was described by the Nernst equation and was .apprx.5-fold greater than that for TPMP, as a result of its greater binding within the mitochondrial matrix. DecylTPP was also taken up extensively by cells, indicating that increased hydrophobicity enhanced uptake. Both MitoQ and DecylTPP were taken up very rapidly into cells, reaching a steady state within 15 min, compared with .apprx.8 h for TPMP. This far faster uptake was the result of the increased rate of passage of hydrophobic TPP mols. through the plasma membrane. Within cells MitoQ was predominantly located within mitochondria, where it was rapidly reduced to the ubiquinol form, consistent with its protective effects in cells and *in vivo* being due to the ubiquinol antioxidant. The strong influence of hydrophobicity on TPP cation uptake into mitochondria within cells facilitates the rational design of mitochondria-targeted compds. to report on and modify mitochondrial function *in vivo*.

IT 444890-41-9, Mitoquinone

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:352859 CAPLUS

DOCUMENT NUMBER: 148:394354

TITLE: Compositions and methods for treatment of viral diseases

INVENTOR(S): Johansen, Lisa M.; Owens, Christopher M.; Mawhinney, Christina; Chappell, Todd W.; Brown, Alexander T.; Frank, Michael G.; Altmeyer, Ralf

PATENT ASSIGNEE(S): Combinatorx (Singapore) Pre. Ltd., Singapore
 SOURCE: PCT Int. Appl., 237pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2008033466 | A2 | 20080320 | WO 2007-US19932 | 20070913 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20080161324 | A1 | 20080703 | US 2007-900893 | 20070913 |

PRIORITY APPLN. INFO.: US 2006-844463P P 20060914
US 2006-874061P P 20061211

AB Based on the results of the authors screen identifying compds. and combinations of compds. having antiviral activity, the present invention features compns., methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compds. that may be used to treat a viral disease.

IT 845959-50-4, Mitoquinone

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for treatment of viral diseases)


RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 444890-41-9

CMF C37 H44 O4 P



CM 2


CRN 16053-58-0
CMF C H3 O3 S

L3 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:199007 CAPLUS
 DOCUMENT NUMBER: 149:26511
 TITLE: Interactions of positively charged ubiquinone analog (MitoQ10) with DT-diaphorase in liver mitochondria
 AUTHOR(S): Kargin, V. I.; Motovilov, K. A.; Vysokikh, M. Yu.; Yaguzhinskii, L. S.
 CORPORATE SOURCE: A. N. Belozerskii Scientific-Research Institute of Physico-Chemical Biology, M. V. Lomonosov Moscow State University, Moscow, 119991, Russia
 SOURCE: Biologicheskie Membrany (2008), 25(1), 34-40
 CODEN: BIMEE9; ISSN: 0233-4755
 PUBLISHER: Izdatel'stvo Nauka
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian

AB MitoQ - a pos. charged analog of CoQ - has been studied as an electron transport cofactor in liver mitochondria. NADH-dependent DT-diaphorase is able to reduce MitoQ at a high rate. MitoQH2 in the presence of malate can restore an electron flow from NADH to oxygen blocked by rotenone. Respiration restored by MitoQ is blocked by dicumarol, mixothiazol, and antimycin A. Therefore, in the presence of MitoQ the following electron transport chain is operating in mitochondria: NADH → DT-diaphorase → MitoQ → complex III → complex IV → oxygen. It is shown also that MitoQH2 in the presence of malate (but not succinate) reduces oxygen in the o-center of mitochondrial bc1-complex giving superoxide anion. This reactive oxygen species induces opening of non-specific pore, which leads to the block of oxidative phosphorylation. The data obtained allow considering MitoQ as an analog of hydrophilic quinones, such as duroquinone and K3, which are well-known substrates of DT-diaphorase, but not as an analog of a natural ubiquinone.


IT 444890-41-9
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (interactions of pos. charged ubiquinone analog (MitoQ10) with DT-diaphorase in liver mitochondria)

RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



L3 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:164099 CAPLUS
 DOCUMENT NUMBER: 148:206611
 TITLE: Methods for reducing anthracycline-induced toxicity
 INVENTOR(S): Kalyanaraman, Balaraman; Kalivendi, Shasi Vardhan;
 Joseph, Joy
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|--|----------|-----------------|------------|
| US 20080032940 | A1 | 20080207 | US 2007-834799 | 20070807 |
| PRIORITY APPLN. INFO.: | | | US 2006-836247P | P 20060807 |
| AB Methods for treating cancers/tumors include administering to a subject an effective amount of a mitochondria-targeted antioxidant alone or in combination with a chemotherapeutic agents. Likewise, methods for mitigating toxicity associated with a chemotherapeutic agent include administering an effective amount of a mitochondria-targeted antioxidant with a single or with multiple chemotherapeutic agents. The invention relates more particularly to coadministering a mitochondria-targeted antioxidant with a chemotherapeutic agent to attenuate the agent's toxicity to normal cells and to enhance its toxicity to tumor cells. At low micromolar concns., mitochondria-targeted antioxidant MitoQ differentially affected normal cells and tumor cells. MitoQ syngerezized with doxorubicin (DOX) to enhance caspase-3 activity in tumor cell lines (MCF-7, MCF-10A and SH-SY5Y), but not in normal cells lines (CM and 1-19c2). In fact, MitoQ attenuated DOX-induced caspase-3 activity in normal cell lines. | | | | |
| IT 444890-41-9P, MitoQ | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | (as mitochondria-targeted antioxidant; reducing anthracycline-induced toxicity by coadministering mitochondria-targeted antioxidant) | | | |
| RN 444890-41-9 CAPLUS | | | | |
| CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME) | | | | |




IT 336184-91-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as mitochondria-targeted antioxidant; reducing anthracycline-induced toxicity by coadministering mitochondria-targeted antioxidant)

RN 336184-91-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻

L3 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:90893 CAPLUS

DOCUMENT NUMBER: 148:192198

TITLE: Preparation of peptidomimetics as modulators of pharmacokinetic properties of therapeutics by inhibiting cytochrome P450 monooxygenase

INVENTOR(S): Desai, Manoj C.; Hong, Allen Yu; Liu, Hongtao; Xu, Lianhong; Vivian, Randall W.

PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA

SOURCE: PCT Int. Appl., 346pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2008010921 | A2 | 20080124 | WO 2007-US15604 | 20070706 |
| WO 2008010921 | A3 | 20080710 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, | | | | |

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW



RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20080108617 A1 20080508 US 2007-825605 20070706

PRIORITY APPLN. INFO.: US 2006-819315P P 20060707
 US 2006-832371P P 20060721
 US 2007-903228P P 20070223

OTHER SOURCE(S): MARPAT 148:192198

GI




AB The invention is related to the preparation of R8YZ1[CONR1(CR2R2)m]nL1NR3CH[L3A(L4Ar)p]CHR4L2CH[L3A(L4Ar)p]NR5COZ2XR9 [I; L1 = C(R6)2, CO, SO2, NHCO and derivs., OCO; R4, R6 = independently H, heteroalkyl, (un)substituted alkyl; L2 = a covalent bond, C(R6)2, CO; each L3 = independently a covalent bond, (un)substituted alkylene; each L4 = L3, O, CH2O, NH; each A = H, (un)substituted alkyl, aryl, heterocyclyl with the proviso that when A = H, p = 0; Z1, Z2 = independently O, NH and derivs.; Y, X = independently heterocyclyl, heterocyclylalkyl; each Ar = independently (un)substituted (hetero)aryl; R1, R3, R5 = independently H, (un)substituted aryl/alkyl; each R2 = independently H, (un)substituted arylhetero/hydroxy/amino/alkyl, alkylene-CO2H, alkylene-CO-alkyl, etc.; R8, R9 are each one or more H's or substituents selected from Cl, CN, (un)substituted alkyl, aryl, heterocyclyl; m = 1-2; n = 0-1; each p = independently 0-1], their pharmaceutically acceptable salts, solvates and esters, and compns. containing them which improve the pharmacokinetics of a co-administered drug which is metabolized by cytochrome P 450 monooxygenase. Thus, a multi-step synthesis using 2-isopropyl-4-

[(methylamino)methyl]-1,3-thiazole, (2S)-2-amino-4-[(tert-butoxycarbonyl)amino]butanoic acid Me ester, amine II and (BrCH₂CH₂)₂₀ was given for III. III inhibited CYP450 3A4 (IC₅₀ = 80–150 nM), CYP450 2C9 (IC₅₀ = 1,000–10,000 nM) and protease (EC₅₀ > 20,000 nM in an anti HIV-1 cell culture assay). I alone or in combination with one or more addnl. therapeutic agents which are metabolized by cytochrome P 450 monooxygenase are useful for treating a viral infection, e.g. HIV (no data).

IT 444890-41-9, MitoQ
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compds. as modulators of pharmacokinetic properties of therapeutic agents)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



L3 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:62861 CAPLUS

DOCUMENT NUMBER: 148:182855

TITLE: Is Antioxidant Potential of the Mitochondrial Targeted Ubiquinone Derivative MitoQ Conserved in Cells Lacking mtDNA?

AUTHOR(S): Lu, Chao; Zhang, Dawei; Whiteman, Matthew; Armstrong, Jeffrey S.

CORPORATE SOURCE: Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

SOURCE: Antioxidants & Redox Signaling (2008), 10(3), 651-660

CODEN: ARSIF2; ISSN: 1523-0864

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB MitoQ was developed as a mitochondrial targeted antioxidant for diseases associated with oxidative stress. Here we show that MitoQ blocks the generation of reactive oxygen species (ROS) and mitochondrial protein thiol oxidation, and preserves mitochondrial function and ultrastructure after glutathione (GSH) depletion. Furthermore, the antioxidant effect of MitoQ is conserved in cells lacking mitochondrial DNA, indicating that its antioxidant properties do not depend on a functional electron transport chain (ETC). Our results elucidate the antioxidant mechanism of MitoQ and suggest that it may be a useful therapeutic for disorders associated with a dysfunctional ETC and increased ROS production

IT 444890-41-9, MitoQ

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MitoQ antioxidant effect via blocking ROS and protein thiol oxidation, and preserving mitochondria independently of glutathione and electron

transport chain)

RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)





REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:40914 CAPLUS
 DOCUMENT NUMBER: 148:168504
 TITLE: Preparation of purine and thiadeazapurine phosphonate derivatives as modulators of toll-like receptor 7
 INVENTOR(S): Chong, Lee S.; Desai, Manoj C.; Gallagher, Brian; Graupe, Michael; Halcomb, Randall L.; Yang, Hong; Zhang, Jennifer R.
 PATENT ASSIGNEE(S): Gilead Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 273pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2008005555 | A1 | 20080110 | WO 2007-US15615 | 20070706 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20080008682 | A1 | 20080110 | US 2007-825377 | 20070706 |
| PRIORITY APPLN. INFO.: | | | US 2006-819490P | P 20060707 |
| | | | US 2006-832851P | P 20060724 |

OTHER SOURCE(S): MARPAT 148:168504
 GI



AB The present application provides for a compound I [Z = OH, NH₂; X₁ = (un)susbtituted alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene; L₁ = bond, (un)susbtituted arylene, heterocyclylene, carbocyclylene, S, S(:O), SO₂, NR₅, O; X₂ = bond, (un)susbtituted alkylene; L₂ = NR₅, NR₅C(:O), O, S, S(:O), SO₂, bond; R₃ = H, (un)susbtituted alkyl, heteroalkyl, alkenyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; Y₁, Y₂ = bond, O, NR₅, Y₁R₁, Y₂R₂ = ON:CR₆R₇; R₁, R₂ = H, (un)susbtituted alkyl, carbocyclyl, heterocyclyl, alkenyl, alkynyl, arylalkyl, etc.; R₄ = H, halogen, OH, O-alkyl, O-alkylene-OCO₂R₅, OCO₂R₅, SH, NHR₅; R₅, R₆, R₇ = H, (un)susbtituted alkyl, carbocyclyl, heterocyclyl, alkenyl, alkynyl, arylalkyl, heterocyclylalkyl, etc.] or II or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compns. containing such compds., therapeutic methods that include the administration of such compds., and therapeutic methods that include the administration of such compds. with at least one addnl. active agent. Thus, [(3-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)methyl](methyl)phosphinic acid [I; Z= NH₂, R₄ = OH, L₂ = O, R₃ = CH₂CH₂OMe, X₁ = X₂ = CH₂, L₁ = 1,3-phenylene, Y₁R₁ = Me, Y₂R₂ = OH] was prepared from 6-chloroadenine via N-alkylation with 3-(BrCH₂)C₆H₄CO₂Me, alkoxylation with MeOCH₂CH₂OH, reesterification with MeI, bromination with Br₂, Dibal-H reduction, methanolysis with NaOMe/MeOH, acid hydrolysis, bromination with PBr₃, phosphorylation with MeP(OEt)₂ and acid hydrolysis under microwave irradiation. The toll-like receptor 7 modulating activity of I and II were investigated (no data).

IT 444890-41-9, MitoQ


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compds. as modulators of Toll-like receptor 7 useful in combination therapy and prevention of TLR7 activation-related diseases)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-

yl)decyl]triphenyl- (CA INDEX NAME)



L3 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1220757 CAPLUS

DOCUMENT NUMBER: 148:2715

TITLE: Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis

AUTHOR(S): Doughan, Abdulrahman K.; Dikalov, Sergey I.

CORPORATE SOURCE: Free Radical in Medicine Core, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA

SOURCE: Antioxidants & Redox Signaling (2007), 9(11), 1825-1836

CODEN: ARSIF2; ISSN: 1523-0864

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The mitochondria-targeted drug mitoquinone (MitoQ) has been used as an antioxidant that may selectively block mitochondrial oxidative damage; however, it has been recently suggested to increase reactive oxygen species (ROS) generation in malate- and glutamate-fueled mitochondria. To address this controversy, we studied the effects of MitoQ on endothelial and mitochondrial ROS production. We found that in a cell-free system with flavin-containing enzyme cytochrome P 450 reductase, MitoQ is a very efficient redox cycling agent and produced more superoxide compared with equal concns. of menadione (10-1000 nM). Treatment of endothelial cells with MitoQ resulted in a dramatic increase in superoxide production. In isolated mitochondria, MitoQ increased complex I-driven mitochondrial ROS production, whereas supplementation with ubiquinone-10 had no effect on ROS production. Similar results were observed in mitochondria isolated from endothelial cells incubated for 1 h with MitoQ. Inhibitor anal. suggested that the redox cycling of MitoQ occurred at two sites on complex I, proximal and distal to the rotenone-binding site. This was confirmed by demonstrating the redox cycling of MitoQ on purified mitochondrial complex I as well as NADH-fueled submitochondrial particles. Mitoquinone time- and dose-dependently increased endothelial cell apoptosis. These findings demonstrate that MitoQ may be prooxidant and proapoptotic because its quinone group can participate in redox cycling and superoxide production. In light of these results, studies using mitoquinone as an antioxidant should be interpreted with caution.


IT 845959-50-4

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis)

RN 845959-50-4 CAPLUS**CN** Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 2

CRN 16053-58-0
 CMF C H3 O3 S



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1030540 CAPLUS

DOCUMENT NUMBER: 147:481558

TITLE: Mitochondrial uncouplers with an extraordinary dynamic range

AUTHOR(S): Lou, Phing-How; Hansen, Birgit S.; Olsen, Preben H.; Tullin, Soren; Murphy, Michael P.; Brand, Martin D.

CORPORATE SOURCE: MRC Dunn Human Nutrition Unit, Cambridge, CB2 2XY, UK

SOURCE: Biochemical Journal (2007), 407(1), 129-140

CODEN: BIJOAK; ISSN: 0264-6021

PUBLISHER: Portland Press Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB We have discovered that some weak uncouplers (typified by butylated hydroxytoluene) have a dynamic range of more than 106 in vitro: the concentration

giving measurable uncoupling is less than one millionth of the concentration causing full uncoupling. They achieve this through a high-affinity interaction with the mitochondrial adenine nucleotide translocase that causes significant but limited uncoupling at extremely low uncoupler concns., together with more conventional uncoupling at much higher concns. Uncoupling at the translocase is not by a conventional weak acid/anion cycling mechanism since it is also caused by substituted triphenylphosphonium mols., which are not anionic and cannot protonate.


Covalent attachment of the uncoupler to a mitochondrially targeted hydrophobic cation sensitizes it to membrane potential, giving a small addnl. effect. The wide dynamic range of these uncouplers in isolated mitochondria and intact cells reveals a novel allosteric activation of proton transport through the adenine nucleotide translocase and provides a promising starting point for designing safer uncouplers for obesity therapy.

IT 845959-50-4 845959-58-2 954111-83-2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (mitochondrial uncouplers with extraordinary dynamic range)
 RN 845959-50-4 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 444890-41-9
 CMF C37 H44 O4 P


CM 2

CRN 16053-58-0
 CMF C H3 O3 S


RN 845959-58-2 CAPLUS
 CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 794485-93-1
 CMF C30 H30 O4 P




CM 2


CRN 16053-58-0
CMF C H3 O3 S

RN 954111-83-2 CAPLUS
 CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 794485-94-2
CMF C32 H34 O4 P

CM 2


CRN 16053-58-0
CMF C H3 O3 S

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:965666 CAPLUS
 DOCUMENT NUMBER: 148:135860
 TITLE: Mitochondria-targeted antioxidants do not prevent tumor necrosis factor-induced necrosis of L929 cells
 AUTHOR(S): Jarvis, Reagan M.; Goettert, Jana; Murphy, Michael P.; Ledgerwood, Elizabeth C.
 CORPORATE SOURCE: Department of Biochemistry, University of Otago, Dunedin, N. Z.
 SOURCE: Free Radical Research (2007), 41(9), 1041-1046
 CODEN: FRARER; ISSN: 1071-5762
 PUBLISHER: Informa Healthcare
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Mitochondrial production of reactive oxygen species (ROS) is widely reported as a central effector during TNF-induced necrosis. The effect of a family of mitochondria-targeted antioxidants on TNF-induced necrosis of L929 cells was studied. While the commonly used lipid-soluble antioxidant BHA effectively protected cells from TNF-induced necrosis, the mitochondria-targeted antioxidants MitoQ3, MitoQ5, MitoQ10 and MitoPBN had no effect on TNF-induced necrosis. Since BHA also acts as an uncoupler of mitochondrial membrane potential, two addnl. uncouplers were tested. FCCP and CCCP both provided dose-dependent inhibition of TNF-induced necrosis. In conclusion, the generation of mitochondrial ROS may not be necessary for TNF-induced necrosis. Instead, these results suggest alternative mitochondrial functions, such as a respiration-dependent process, are critical for necrotic death.

IT 764723-90-2 845959-57-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitochondria-targeted antioxidants do not prevent tumor necrosis factor-induced necrosis of L929 cells)
 RN 764723-90-2 CAPLUS
 CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 845959-57-1 CAPLUS
 CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:922908 CAPLUS

DOCUMENT NUMBER: 147:356077

TITLE: Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone

AUTHOR(S): Rocha, Milagros; Victor, Victor Manuel

CORPORATE SOURCE: Department of Pharmacology, Faculty of Medicine, Universitat of Valencia, Valencia, Spain

SOURCE: Medical Science Monitor (2007), 13(7), RA132-RA145

CODEN: MSMOFR; ISSN: 1234-1010

PUBLISHER: International Scientific Literature, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Mitochondria have long been known to play a critical role in maintaining the bioenergetic status of cells under physiol. conditions. Mitochondria produce large amts. of free radicals, and mitochondrial oxidative damage can contribute to a range of degenerative conditions including cardiovascular diseases (CVDs). Although the mol. mechanisms responsible for mitochondrion-mediated disease processes are not correctly understood, oxidative stress seems to play an important role.

Consequently, the selective inhibition of mitochondrial oxidative damage is an obvious therapeutic strategy. This review considers the process of CVD from a mitochondrial perspective and provides a summary of the following areas: reactive oxygen species (ROS) production and its role in pathophysiol. processes such as CVD, currently available antioxidants and possible reasons for their efficacy and inefficacy in ameliorating oxidative stress-mediated diseases, and recent developments in mitochondria-targeted antioxidants that concentrate on the matrix-facing surface

of the inner mitochondrial membrane. These mitochondrion-targeted antioxidants have been developed by conjugating the lipophilic triphenylphosphonium cation to antioxidant moieties such as ubiquinol. These compds. pass easily through biol. membranes and, due to their pos. charge, they accumulate several-hundred-fold within mitochondria. In this way they protect against mitochondrial oxidative damage and show potential as a future therapy for CVDs.

IT 845959-50-4, Mitoquinone

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

10/568, 655

07/27/2008

(loss of control of reactive oxygen species formation in mitochondria leads to pathol. of cardiovascular disease in animals and mitoquinone protect against mitochondrial oxidative damage and showed potential as future therapy for CVD)


RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 444890-41-9


CMF C37 H44 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S



REFERENCE COUNT: 126 THERE ARE 126 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:818711 CAPLUS

DOCUMENT NUMBER: 147:335184

TITLE: Drug evaluation: MitoQ - a mitochondrial-targeted antioxidant

AUTHOR(S): Tauskela, Joseph S.

CORPORATE SOURCE: Institute for Biological Sciences, Synaptic Pathophysiology Group, National Research Council, Ottawa, ON, K1A 0R6, Can.

SOURCE: IDrugs (2007), 10(6), 399-412
CODEN: IDRUFN; ISSN: 1369-7056

PUBLISHER: Thomson Scientific

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. MitoQ is an orally active antioxidant that has the ability to target mitochondrial dysfunction. The agent is currently under


development by Antipodean Pharmaceuticals Inc and is in phase II clin. trials for Parkinson's disease and liver damage associated with HCV infection. MitoQ demonstrated encouraging preclin. results in numerous studies in isolated mitochondria, cells and tissues undergoing oxidative stress and apoptotic death. The aim of MitoQ is to not only mimic the role of the endogenous mitochondrial antioxidant coenzyme Q10 (CoQ10), but also to substantially augment the antioxidant capacity of the coenzyme to supraphysiolog. levels in a mitochondrial membrane potential-dependent manner. MitoQ represents the first foray into the clinic of an attempt to deliver an antioxidant to an intracellular region that is responsible for the formation of increased levels of potentially deleterious reactive oxygen species. Results from the clin. trials with MitoQ will have important repercussions regarding the relevance of a mitochondria-targeted approach.

IT 444890-41-9, MitoQ

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mitochondrial-targeted antioxidant MitoQ)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 91 THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:739270 CAPLUS

DOCUMENT NUMBER: 147:273456

TITLE: Quantitation and metabolism of mitoquinone, a mitochondria-targeted antioxidant, in rat by liquid chromatography/tandem mass spectrometry

AUTHOR(S): Li, Yan; Zhang, Hu; Fawcett, J. Paul; Tucker, Ian G.

CORPORATE SOURCE: School of Pharmacy, University of Otago, Dunedin, N.Z.

SOURCE: Rapid Communications in Mass Spectrometry (2007), 21(13), 1958-1964

CODEN: RCMSEF; ISSN: 0951-4198

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mitoquinone (MitoQ10 mesylate) is a mitochondria-targeted antioxidant undergoing development for the treatment of neurodegenerative diseases. The aim of this study was to develop and validate an assay based on liquid chromatog./tandem mass spectrometry (LC/MS/MS) to determine mitoquinone and to detect and identify the metabolites of MitoQ10 in rat plasma after an oral dose. After a simple protein precipitation step, plasma samples were analyzed by

reversed-phase liquid chromatog. using gradient elution with acetonitrile/water/formic acid. Electrospray ionization in the pos. ion mode with multiple reaction monitoring (MRM) was used to analyze mitoquinone employing the deuterated compound (d3-MitoQ10 mesylate) as internal standard. The calibration curve for mitoquinone was linear over the concentration range 0.5-250 ng/mL with a correlation coefficient >0.995. The method


was sensitive (limit of quantitation 0.5 ng/mL) and had acceptable accuracy (relative error <8.7%) and precision (intra- and inter-day coefficient of variation <12.4%). Recoveries of mitoquinone at concns. of 1.5, 20 and 200 ng/mL were in the range 87-114%. The method was successfully applied to a pharmacokinetic study in rat after a single oral dose in which four metabolites of MitoQ10 were tentatively identified as hydroxylated MitoQ10, desmethyl MitoQ10 and the glucuronide and sulfate conjugates of the quinol form of MitoQ10.

IT 444890-41-9

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(quantitation and metabolism of mitochondria-targeted antioxidant mitoquinone in rat)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:542355 CAPLUS

DOCUMENT NUMBER: 147:157119

TITLE: Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases

AUTHOR(S): Victor, V. M.; Rocha, M.

CORPORATE SOURCE: Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain

SOURCE: Current Pharmaceutical Design (2007), 13(8), 845-863

CODEN: CPDEFP; ISSN: 1381-6128

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Mitochondria produce large amounts of free radicals and play an important role in the life and death of a cell. Thus, mitochondrial oxidative damage and dysfunction contribute to a number of cell pathologies that manifest themselves through a range of conditions including ischemia-reperfusion injury, sepsis, diabetes, atherosclerosis and, consequently, cardiovascular diseases (CVD). In fact, endothelial dysfunction, characterized by a loss of nitric oxide (NO) bioactivity, occurs early on in the development of atherosclerosis, and its future


vascular complications. Although the mol. mechanisms responsible for mitochondria-mediated disease processes are not yet clear, oxidative stress seems to play an important role. This review considers the process of CVD from a mitochondrial perspective. Accordingly, strategies for the targeted delivery of antioxidants to mitochondria are being developed. In this review, we will provide a summary of the following areas: the cellular metabolism of reactive oxygen species (ROS) and its role in pathophysiol. processes such as CVD; currently available antioxidants and possible reasons for their efficacy and inefficacy in ameliorating oxidative stress-mediated diseases; recent developments in mitochondrially-targeted antioxidants that concentrate on the matrix-facing surface of the inner mitochondrial membrane and therefore protect against mitochondrial oxidative damage, and their therapeutic potential for future treatment of CVDs. More pre-clin. and clin. studies, however, are necessary in order to evaluate the effectiveness and toxicity of mitochondrially-targeted antioxidants.

IT 444890-41-9, MitoQ

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(targeting antioxidants to mitochondria with a potential new therapeutic strategy for cardiovascular diseases)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 156 THERE ARE 156 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:522753 CAPLUS

DOCUMENT NUMBER: 147:202729

TITLE: Mitochondrial targeting of quinones: Therapeutic implications

AUTHOR(S): Cocheme, Helena M.; Kelso, Geoffrey F.; James, Andrew M.; Ross, Meredith F.; Trnka, Jan; Mahendiran, Thabo; Asin-Cayuela, Jordi; Blaikie, Frances H.; Manas, Abdul-Rahman B.; Porteous, Carolyn M.; Adlam, Victoria J.; Smith, Robin A. J.; Murphy, Michael P.

CORPORATE SOURCE: MRC Dunn Human Nutrition Unit, Cambridge, CB2 2XY, UK

SOURCE: Mitochondrion (2007), 7(Suppl.), S94-S102

CODEN: MITOCN; ISSN: 1567-7249

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. Mitochondrial oxidative damage contributes to a range of degenerative diseases. Ubiquinones have been shown to protect

mitochondria from oxidative damage, but only a small proportion of externally administered ubiquinone is taken up by mitochondria. Conjugation of the lipophilic triphenylphosphonium cation to a ubiquinone moiety has produced a compound, MitoQ, which accumulates selectively into mitochondria. MitoQ passes easily through all biol. membranes and, because of its pos. charge, is accumulated several hundred-fold within mitochondria driven by the mitochondrial membrane potential. MitoQ protects mitochondria against oxidative damage in vitro and following oral delivery, and may therefore form the basis for mitochondria-protective therapies.

IT 444890-41-9, MitoQ
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitochondrial targeting of quinones and therapeutic implications)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:513564 CAPLUS

DOCUMENT NUMBER: 147:160001

TITLE: Interaction of the Mitochondria-targeted Antioxidant MitoQ with Phospholipid Bilayers and Ubiquinone Oxidoreductases

AUTHOR(S): James, Andrew M.; Sharpley, Mark S.; Manas, Abdul-Rahman B.; Frerman, Frank E.; Hirst, Judy; Smith, Robin A. J.; Murphy, Michael P.

CORPORATE SOURCE: Medical Research Council Dunn Human Nutrition Unit, Cambridge, CB2 2XY, UK

SOURCE: Journal of Biological Chemistry (2007), 282(20), 14708-14718

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB MitoQ₁₀ is a ubiquinone that accumulates within mitochondria driven by a conjugated lipophilic triphenylphosphonium cation (TPP⁺). Once there, MitoQ₁₀ is reduced to its active ubiquinol form, which has been used to prevent mitochondrial oxidative damage and to infer the involvement of reactive oxygen species in signaling pathways. Here we show MitoQ₁₀ is effectively reduced by complex II, but is a poor substrate for complex I, complex III, and electron-transferring flavoprotein (ETF):quinone oxidoreductase (ETF-QOR). This differential reactivity could be explained

if the bulky TPP⁺ moiety sterically hindered access of the ubiqinone group to enzyme active sites with a long, narrow access channel. Using a combination of mol. modeling and an uncharged analog of MitoQ10 with similar sterics (tritylQ10), we infer that the interaction of MitoQ10 with complex I and ETF-QOR, but not complex III, is inhibited by its bulky TPP⁺ moiety. To explain its lack of reactivity with complex III we show that the TPP⁺ moiety of MitoQ10 is ineffective at quenching pyrene fluorophors deeply buried within phospholipid bilayers and thus is positioned near the membrane surface. This superficial position of the TPP⁺ moiety, as well as the low solubility of MitoQ10 in non-polar organic solvents, suggests that the


concentration of the entire MitoQ10 mol. in the membrane core is very limited. As overlaying MitoQ10 onto the structure of complex III indicates that MitoQ10 cannot react with complex III without its TPP⁺ moiety entering the low dielec. of the membrane core, we conclude that the TPP⁺ moiety does anchor the tethered ubiqinol group out of reach of the active site(s) of complex III, thus explaining its slow oxidation. In contrast the ubiqinone moiety of MitoQ10 is able to quench fluorophors deep within the membrane core, indicating a high concentration of the ubiqinone moiety within the membrane and explaining its good anti-oxidant efficacy. These findings will facilitate the rational design of future mitochondria-targeted mols.

IT 444890-41-9, MitoQ

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(interaction of mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiqinone oxidoreductases)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:407185 CAPLUS

DOCUMENT NUMBER: 147:63256

TITLE: Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers

AUTHOR(S): Li, Yan; Fawcett, J. Paul; Zhang, Hu; Tucker, Ian G.

CORPORATE SOURCE: School of Pharmacy, University of Otago, Dunedin, N.Z.

SOURCE: Journal of Pharmacy and Pharmacology (2007), 59(4), 503-511

CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:63256

AB Mitoquinone (MitoQ10 mesylate) is a mitochondria-targeted antioxidant formulated for oral administration in the treatment of neurodegenerative diseases. We have investigated the absorption and metabolism of MitoQ10 in Caco-2 cell monolayers. The intracellular accumulation of MitoQ10 was 18-41% of the total amount of MitoQ10 added. Some of the intracellular MitoQ10 was reduced to mitoquinol and subsequently metabolized to glucuronide and sulfate conjugates. Transport of MitoQ10 was polarized with the apparent permeability (Papp) from basolateral (BL) to apical (AP) ($Papp_{BL \rightarrow AP}$) being >2.5-fold the Papp from apical to basolateral ($Papp_{AP \rightarrow BL}$). In the presence of 4% bovine serum albumin on the basolateral side, the $Papp_{AP \rightarrow BL}$ value increased 7-fold compared with control. The $Papp_{BL \rightarrow AP}$ value decreased by 26%, 31%, and 61% in the presence of verapamil 100 μ M, ciclosporin 10 and 30 μ M, resp., whereas the $Papp_{AP \rightarrow BL}$ value increased 71% in the presence of ciclosporin 30 μ M. Apical efflux of mitoquinol sulfate and mitoquinol glucuronide conjugates was significantly decreased by ciclosporin 30 μ M and the breast cancer receptor protein (BCRP) inhibitor, reserpine 25 μ M, resp. These results suggested that the bioavailability of MitoQ10 may be limited by intracellular metabolism and the action of P-glycoprotein and BCRP. However, the dramatic increase in absorptive Papp in the presence of bovine serum albumin on the receiver side suggests these barrier functions may be less significant in-vivo.

IT 845959-50-4, Mitoquinone mesylate

RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transport and metabolism of MitoQ10 as mitochondria-targeted antioxidant, in Caco-2 cell monolayers)


RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 444890-41-9


CMF C37 H44 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:70572 CAPLUS

DOCUMENT NUMBER: 146:182912

TITLE: High Concentration of Antioxidants N-Acetylcysteine and Mitoquinone-Q Induces Intercellular Adhesion Molecule 1 and Oxidative Stress by Increasing Intracellular Glutathione

AUTHOR(S): Mukherjee, Tapan K.; Mishra, Anurag K.; Mukhopadhyay, Srirupa; Hoidal, John R.

CORPORATE SOURCE: Department of Internal Medicine, Pulmonary Division, University of Utah Health Science Center, Salt Lake City, UT, 84112, USA

SOURCE: Journal of Immunology (2007), 178(3), 1835-1844
CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal


LANGUAGE: English

AB In endothelial cells, the intracellular level of glutathione is depleted during offering protection against proinflammatory cytokine TNF- α -induced oxidative stress. Administration of anti-inflammatory drugs, i.e., N-acetylcysteine (NAC) or mitoquinone-Q (mito-Q) in low concns. in the human pulmonary aortic endothelial cells offered protection against depletion of reduced glutathione and oxidative stress mediated by TNF- α . However, this study addressed that administration of NAC or mto-Q in high concns. resulted in a biphasic response by initiating an enhanced generation of both reduced glutathione and oxidized glutathione and enhanced production of reactive oxygen species, along with carbonylation and glutathionylation of the cellular proteins. This study further addressed that I κ B kinase (IKK), a phosphorylation-dependent regulator of NF- κ B, plays an important regulatory role in the TNF- α -mediated induction of the inflammatory cell surface mol. ICAM-1. Of the two catalytic subunits of IKK (IKK α and IKK β), low concns. of NAC and mto-Q activated IKK α activity, thereby inhibiting the downstream NF- κ B and ICAM-1 induction by TNF- α . High concns. of NAC and mto-Q instead caused glutathionylation of IKK α , thereby inhibiting its activity that in turn enhanced the downstream NF- κ B activation and ICAM-1 expression by TNF- α . Thus, establishing IKK α as an anti-inflammatory mol. in endothelial cells is another focus of this study. This is the first report that describes a stressful situation in the endothelial cells created by excess of antioxidative and anti-inflammatory agents NAC and mto-Q, resulting in the generation of reactive oxygen species, carbonylation and glutathionylation of cellular proteins, inhibition of IKK α activity, and up-regulation of ICAM-1 expression.

IT 444890-41-9, MitoQ

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(high concentration of antioxidants N-acetylcysteine and mitoquinone-Q induces

ICAM-1 and oxidative stress by increasing intracellular glutathione)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1348478 CAPLUS
 DOCUMENT NUMBER: 146:178916
 TITLE: Reactive Oxygen and Targeted Antioxidant Administration in Endothelial Cell Mitochondria
 AUTHOR(S): O'Malley, Yunxia; Fink, Brian D.; Ross, Nicolette C.; Prisinzano, Thomas E.; Sivitz, William I.
 CORPORATE SOURCE: Iowa City Veterans Affairs Medical Center, Department of Internal Medicine, Division of Endocrinology and Metabolism and the College of Pharmacy, Division of Medicinal and Natural Products Chemistry, University of Iowa, Iowa City, IA, 52242, USA
 SOURCE: Journal of Biological Chemistry (2006), 281(52), 39766-39775
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We used fluorescent probes and EPR to study the mechanism(s) underlying reactive oxygen species (ROS) production by endothelial cell mitochondria and the action of mitoquinol (MitoQ), a mitochondria-targeted antioxidant. ROS measured by fluorescence resulted from complex I superoxide released to the matrix and converted to H₂O₂. In contrast, EPR largely detected superoxide generated at complex III and effluxed outward. ROS fluorescence by mitochondria fueled by the complex II substrate, succinate, was substantial but markedly inhibited by rotenone. Superoxide, detected by EPR, in succinate-fueled mitochondria was not inhibited by rotenone and likely derived from semiquinone formation at complex III. Mitoquinol decreased H₂O₂ fluorescence by succinate-fueled mitochondria but had little effect on the EPR signal for superoxide. This was not associated with a detectable decrease in membrane potential. Mitoquinol markedly enhanced ROS fluorescence in mitochondria fueled by the complex I substrates, glutamate and malate. Inhibitor studies suggested that this occurred in complex I, at one or more Q binding pockets. The above effects of mitoquinol were determined in mitochondria isolated and subsequently exposed to the targeted antioxidant. However, similar effects were observed in mitochondria after antecedent exposure to mitoquinol/mitoquinone in culture, suggesting that the agent is retained


after isolation of the organelles. In conclusion, ROS production in bovine aortic endothelial cell mitochondria results largely from reverse transport to complex I and through the Q cycle in complex III. Mitoquinol blocks ROS from reverse electron transport but increases superoxide production derived from forward transport. These effects likely occur at one or more Q binding sites in complex I.

IT 444890-41-9, MitoQ

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MitoQ acts in complex I to block ROS generated by reverse electron transport but increases superoxide production associated with forward electron transport)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1112822 CAPLUS

DOCUMENT NUMBER: 145:495544

TITLE: Antitumor sustained-release injection containing taxane and its synergistic agent

INVENTOR(S): Liu, Yuyan

PATENT ASSIGNEE(S): Jinan Kangquan Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 34pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|------------------|----------|
| CN 1846689 | A | 20061018 | CN 2006-10200114 | 20060210 |
| PRIORITY APPLN. INFO.: | | | CN 2006-10200114 | 20060210 |

AB The patent antitumor sustained-release injection is comprised of (A) sustained-release microsphere comprising antitumor effective constituent 0.5-60%, sustained-release adjuvant 40-99% and suspending agent 0.0-30.0%; and (B) solvent. The antitumor effective constituent is taxane and/or the taxane synergistic agent which is selected from antimitotic drugs, alkylating agents and/or antimetabolite agents. The taxane is selected from taxol, docetaxel, paclitaxel-2'-hydroxy, 10-deacetylbaicatin III, and 7-epi-taxol. The antimitotic drug is selected from one of podophyllotoxin, mitonafide, mitotane, colchicine, colchisal, naphthol,

cytochalasin, etc., or the mixture thereof. The alkylating agent is selected from one of cyclophosphamide, melphalan, chlorambucil, ifosfamide, etc., or the mixture thereof. The antimetabolite agent is selected from one of 6-mercaptopurine, 5-fluorouracil, alimta, alimta disodium, etc., or the mixture thereof. The sustained-release adjuvant is selected from one of (a) polylactic acid; (b) Polyglycolic acid-hydroxy acetic acid copolymer; (c) polifeprosan; (d) ethene-vinyl acetate copolymer; (e) difatty acid-sebacic acid copolymer; (f) poly(erucic acid dimer-sebacic acid) copolymer; (g) poly(fumaric acid-sebacic acid) copolymer; and (h) xylitol, oligosaccharide, chondroitin, chitin, hyaluronic acid, collagens, gelatin, etc.; or the mixture thereof. The suspending agent is one of (a) 0.5-3.0 % (sodium) CM-cellulose; (b) 5-15 % mannitol; (c) 5-15 % sorbitol; (d) 0.1-1.5 % surfactant; (e) 0.1-0.5 % tween 20; or (f) (iodine) glycerin, dimethicone, propylene glycol, or carbomer; or the mixture thereof. Said sustained-release preparation can reduce toxic reaction, at the same time can increase selectively drug concentration, and enhance therapeutic effectiveness.


IT 444890-41-9, Mito-Q

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor sustained-release injection containing taxane and its synergistic agent)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



L3 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1067714 CAPLUS

DOCUMENT NUMBER: 145:419306

TITLE: Preparation of mitoquinone derivatives as mitochondrially targeted antioxidants

INVENTOR(S): Taylor, Kenneth Martin; Smith, Robin A. J.

PATENT ASSIGNEE(S): Antipodean Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 57pp., Cont.-in-part of U.S. Ser. No. 172,916.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|------|----------|-----------------|----------|
| US 20060229278 | A1 | 20061012 | US 2006-355518 | 20060215 |

| | | | | |
|--|--|----------|----------------|-------------|
| WO 9926954 | A1 | 19990603 | WO 1998-NZ173 | 19981125 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| US 6331532 | B1 | 20011218 | US 2000-577877 | 20000525 |
| US 20020052342 | A1 | 20020502 | US 2001-968838 | 20011003 |
| US 20030069208 | A1 | 20030410 | US 2002-272914 | 20021018 |
| AU 2003204144 | A1 | 20030612 | AU 2003-204144 | 20030512 |
| AU 2003204144 | B2 | 20070301 | | |
| US 20040106579 | A1 | 20040603 | US 2003-722542 | 20031128 |
| WO 2005019232 | A1 | 20050303 | WO 2004-NZ196 | 20040823 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 20050245487 | A1 | 20051103 | US 2005-172916 | 20050705 |
| US 7232809 | B2 | 20070619 | | |
| US 20070270381 | A1 | 20071122 | US 2007-799779 | 20070502 |
| PRIORITY APPLN. INFO.: | | | WO 1998-NZ173 | A2 19981125 |
| | | | US 2000-577877 | A1 20000525 |
| | | | US 2001-968838 | B1 20011003 |
| | | | US 2002-272914 | B1 20021018 |
| | | | NZ 2003-527800 | A 20030822 |
| | | | NZ 2003-529153 | A 20031023 |
| | | | US 2003-722542 | B1 20031128 |
| | | | NZ 2004-533556 | A 20040614 |
| | | | WO 2004-NZ196 | A1 20040823 |
| | | | US 2005-172916 | A2 20050705 |
| | | | NZ 1997-329255 | A 19971125 |
| | | | AU 1999-16965 | A3 19981125 |
| | | | NZ 1998-329255 | A 19981125 |

OTHER SOURCE(S):

MARPAT 145:419306

GI



AB This invention relates to pharmaceutically acceptable amphiphilic antioxidant compds., compns. and dosage forms comprising the compds. The compds., compns., dosage forms, uses and methods are useful in the treatment of diseases or conditions associated with oxidative stress. Thus, I 1:2 complex β -cyclodextrin with was prepared, and tested for stability and pharmacokinetics.

IT 845959-56-0P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mitoquinone triphenylphosphonium derivs. as mitochondrially targeted antioxidants)

RN 845959-56-0 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 4

CRN 16053-58-0
 CMF C H3 O3 S



IT 845959-52-6P 911841-84-4P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mitoquinone triphenylphosphonium derivs. as mitochondrially targeted antioxidants)

RN 845959-52-6 CAPLUS

CN β-Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (1:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 7585-39-9


10/568, 655

07/27/2008

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2


CRN 845959-50-4

CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9

CMF C37 H44 O4 P



CM 4

CRN 16053-58-0
CMF C H₃ O₃ S


RN 911841-84-4 CAPLUS
 CN β-Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (4:1) (9CI)
 (CA INDEX NAME)

CM 1

CRN 7585-39-9
CMF C₄₂ H₇₀ O₃₅

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 4

CRN 16053-58-0
 CMF C H3 O3 S



IT 845959-50-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of mitoquinone triphenylphosphonium derivs. as mitochondrially targeted antioxidants)

RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 2

CRN 16053-58-0
 CMF C H3 O3 S



IT 764723-90-2P 764723-92-4P 845959-58-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of mitoquinone triphenylphosphonium derivs. as mitochondrially targeted antioxidants)


RN 764723-90-2 CAPLUS

CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)

● I⁻

RN 764723-92-4 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻


RN 845959-58-2 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 794485-93-1


CMF C₃₀ H₃₀ O₄ P



CM 2

CRN 16053-58-0
CMF C H3 O3 S

IT 845959-57-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of mitoquinone triphenylphosphonium derivs. as mitochondrially targeted antioxidants)
 RN 845959-57-1 CAPLUS
 CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻

L3 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:202663 CAPLUS
 DOCUMENT NUMBER: 145:202743
 TITLE: The effects of exogenous antioxidants on lifespan and oxidative stress resistance in *Drosophila melanogaster*
 AUTHOR(S): Magwere, Tapiwanashe; West, Melanie; Riyahi, Kumars;
 Murphy, Michael P.; Smith, Robin A. J.; Partridge,
 Linda

CORPORATE SOURCE: Centre for Research on Aging, Department of Biology,
University College London, London, WC1E 6BT, UK

SOURCE: Mechanisms of Ageing and Development (2006), 127(4),
356-370

CODEN: MAGDA3; ISSN: 0047-6374
Elsevier Ltd.

PUBLISHER:
DOCUMENT TYPE: Journal
LANGUAGE: English


AB We used the fruit fly *Drosophila melanogaster* to test the effects of feeding the superoxide dismutase (SOD) mimetic drugs Euk-8 and -134 and the mitochondria-targeted mitoquinone (MitoQ) on lifespan and oxidative stress resistance of wild type and SOD-deficient flies. Our results reaffirm the findings by other workers that exogenous antioxidant can rescue pathol. associated with compromised defences to oxidative stress, but fail to extend the lifespan of normal, wild type animals. All three drugs showed a dose-dependent increase in toxicity in wild type flies, an effect that was exacerbated in the presence of the redox-cycling drug paraquat. However, important findings from this study were that in SOD-deficient flies, where the antioxidant drugs increased lifespan, the effects were sex-specific and, for either sex, the effects were also variable depending on (1) the stage of development from which the drugs were given, and (2) the magnitude of the dose. These findings place significant constraints on the role of oxidative stress in normal aging.

IT 444890-41-9, MitoQ

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant drug, mitochondria-targeted mitoquinone dose-dependently increased toxicity in wild type flies while it increased lifespan in superoxide dismutase-deficient *Drosophila melanogaster*)

RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:51133 CAPLUS

DOCUMENT NUMBER: 144:121851

TITLE: Use of mitochondrially targeted antioxidant-lipophilic cation conjugate in the treatment of liver diseases and epithelial cancers.

INVENTOR(S): Froehlich, Eleonore; Kvietikova, Ivica; Zatloukal, Kurt; Schatz, Gottfried; Denk, Helmut; Stumptner, Cornelia; Buck, Charles

PATENT ASSIGNEE(S): Oridis Biomed Forschungs- und Entwicklungs G.m.b.H., Austria

SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006005759 | A2 | 20060119 | WO 2005-EP53338 | 20050712 |
| WO 2006005759 | A3 | 20060511 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2005261654 | A1 | 20060119 | AU 2005-261654 | 20050712 |
| CA 2573456 | A1 | 20060119 | CA 2005-2573456 | 20050712 |
| EP 1765413 | A2 | 20070328 | EP 2005-775873 | 20050712 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| CN 1997403 | A | 20070711 | CN 2005-80023193 | 20050712 |
| JP 2008506667 | T | 20080306 | JP 2007-520833 | 20050712 |
| KR 2007030815 | A | 20070316 | KR 2006-725659 | 20061206 |
| US 20070225255 | A1 | 20070927 | US 2007-632149 | 20070212 |
| PRIORITY APPLN. INFO.: | | | EP 2004-103318 | A 20040713 |
| | | | WO 2005-EP53338 | W 20050712 |

OTHER SOURCE(S): MARPAT 144:121851

AB The invention discloses the use of a mitochondrially targeted antioxidant, e.g. derivs. of vitamin E, coenzyme Q10 or a glutathione peroxidase mimetic, in the treatment and prevention of liver diseases and/or epithelial cancers. The invention also discloses pharmaceutical compns. containing the antioxidant(s) intended for such use. Furthermore the invention relates to the manufacture of medicaments containing the antioxidant(s)

useful for such prevention and treatment. Compds. of the invention comprise a lipophilic cation covalently coupled to an antioxidant moiety, e.g. (Ph)3P+XR·Z- (X = linking group; R = antioxidant moiety; Z- = anion).

IT 873653-01-1 873653-02-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitochondrially targeted antioxidant-lipophilic cation conjugate for treatment of liver disease and epithelial cancer)

RN 873653-01-1 CAPLUS


CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide, mixt. with [10-(3,6-dihydroxy-4,5-dimethoxy-2-methylphenyl)decyl]triphenylphosphonium bromide (9CI) (CA INDEX NAME)

CM 1

10/568, 655

07/27/2008


CRN 336184-91-9
CMF C37 H44 O4 P . Br



● Br⁻

CM 2

CRN 299975-19-2
CMF C37 H46 O4 P . Br



● Br⁻


RN 873653-02-2 CAPLUS
CN Phosphonium, [10-(3,6-dihydroxy-4,5-dimethoxy-2-methylphenyl)decyl]triphenyl-, methanesulfonate, mixt. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 845959-55-9
CMF C37 H46 O4 P . C H3 O3 S

CM 2

CRN 747398-82-9
CMF C37 H46 O4 P




CM 3

CRN 16053-58-0
CMF C H3 O3 S

CM 4


CRN 845959-50-4
CMF C37 H44 O4 P . C H3 O3 S

CM 5

CRN 444890-41-9
CMF C37 H44 O4 P

CM 6

CRN 16053-58-0
CMF C H3 O3 S




L3 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:584282 CAPLUS
 DOCUMENT NUMBER: 143:241657
 TITLE: Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury
 AUTHOR(S): Adlam, Victoria J.; Harrison, Joanne C.; Porteous, Carolyn M.; James, Andrew M.; Smith, Robin A. J.; Murphy, Michael P.; Sammut, Ivan A.
 CORPORATE SOURCE: Department of Chemistry, University of Otago, Dunedin, N. Z.
 SOURCE: FASEB Journal (2005), 19(9), 1088-1095
 CODEN: FAJOEC; ISSN: 0892-6638
 PUBLISHER: Federation of American Societies for Experimental Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Mitochondrial oxidative damage contributes to a wide range of pathologies, including cardiovascular disorders and neurodegenerative diseases. Therefore, protecting mitochondria from oxidative damage should be an effective therapeutic strategy. However, conventional antioxidants have limited efficacy due to the difficulty of delivering them to mitochondria *in situ*. To overcome this problem, we developed mitochondria-targeted antioxidants, typified by MitoQ, which comprises a lipophilic triphenylphosphonium (TPP) cation covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane potential, the TPP cation localizes several hundred-fold within mitochondria, selectively preventing mitochondrial oxidative damage. To test whether MitoQ was active *in vivo*, we chose a relevant form of mitochondrial oxidative damage: cardiac ischemia-reperfusion injury. Feeding MitoQ to rats significantly decreased heart dysfunction, cell death, and mitochondrial damage after ischemia-reperfusion. This protection was due to the antioxidant activity of MitoQ within mitochondria, as an untargeted antioxidant was ineffective and accumulation of the TPP cation alone gave no protection. Therefore, targeting antioxidants to mitochondria *in vivo* is a promising new therapeutic strategy in the wide range of human diseases such as Parkinson's disease, diabetes, and Friedreich's ataxia where mitochondrial oxidative damage underlies the pathology.

IT 444890-41-9, MitoQ
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury)

RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:463624 CAPLUS
 DOCUMENT NUMBER: 143:148390
 TITLE: Interactions of Mitochondria-targeted and Untargeted Ubiquinones with the Mitochondrial Respiratory Chain and Reactive Oxygen Species: implications for the use of exogenous ubiquinones as therapies and experimental tools
 AUTHOR(S): James, Andrew M.; Cocheme, Helena M.; Smith, Robin A. J.; Murphy, Michael P.
 CORPORATE SOURCE: Medical Research Council Dunn Human Nutrition Unit, Cambridge, CB2 2XY, UK
 SOURCE: Journal of Biological Chemistry (2005), 280(22), 21295-21312
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Antioxidants, such as ubiquinones, are widely used in mitochondrial studies as both potential therapies and useful research tools. However, the effects of exogenous ubiquinones can be difficult to interpret because they can also be pro-oxidants or electron carriers that facilitate respiration. Recently we developed a mitochondria-targeted ubiquinone (MitoQ10) that accumulates within mitochondria. MitoQ10 has been used to prevent mitochondrial oxidative damage and to infer the involvement of mitochondrial reactive oxygen species in signaling pathways. However, uncertainties remain about the mitochondrial reduction of MitoQ10, its oxidation by the respiratory chain, and its pro-oxidant potential. Therefore, we compared MitoQ analogs of varying alkyl chain lengths (MitoQ_n, n = 3-15) with untargeted exogenous ubiquinones. We found that MitoQ10 could not restore respiration in ubiquinone-deficient mitochondria because oxidation of MitoQ analogs by complex III was minimal. Complex II and glycerol 3-phosphate dehydrogenase reduced MitoQ analogs, and the rate depended on chain length. Because of its rapid reduction and negligible oxidation, MitoQ10 is a more effective antioxidant against lipid peroxidation, peroxynitrite and superoxide. Paradoxically, exogenous ubiquinols also autoxidize to generate superoxide, but this requires their deprotonation in the aqueous phase. Consequently, in the presence of phospholipid bilayers, the rate of autoxidation is proportional to ubiquinol hydrophilicity. Superoxide production by MitoQ10 was insufficient to damage aconitase but did lead to hydrogen peroxide production and nitric oxide consumption, both of which may affect cell signaling pathways. Our results comprehensively describe the

interaction of exogenous ubiquinones with mitochondria and have implications for their rational design and use as therapies and as research tools to probe mitochondrial function.


IT 444890-41-9 794485-93-1 794485-94-2
 794485-95-3
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)




RN 794485-93-1 CAPLUS
 CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl- (CA INDEX NAME)



RN 794485-94-2 CAPLUS
 CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl- (CA INDEX NAME)



RN 794485-95-3 CAPLUS
 CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:182678 CAPLUS

DOCUMENT NUMBER: 142:254662

TITLE: Mitoquinone derivatives used as mitochondrially targeted antioxidants, and preparation thereof

INVENTOR(S): Murphy, Michael Patrick; Smith, Robin

PATENT ASSIGNEE(S): Antipodean Biotechnology Limited, N. Z.

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFO. NO. 60

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2005019233 | A1 | 20050303 | WO 2004-NZ197 | 20040823 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003204144 | A1 | 20030612 | AU 2003-204144 | 20030512 |
| AU 2003204144 | B2 | 20070301 | | |
| US 20070238709 | A1 | 20071011 | US 2007-568654 | 20070222 |
| RITY APPLN. INFO.: | | | NZ 2003-527800 | A 20030822 |
| | | | NZ 2003-529153 | A 20031023 |
| | | | NZ 2004-533555 | A 20040614 |
| | | | AU 1999-16965 | A3 19981125 |
| | | | NZ 1998-329255 | A 19981125 |
| | | | WO 2004-NZ197 | W 20040823 |

OTHER SOURCE(S): CASREACT 142:254662; MARPAT 142:254662

AB This invention discloses methods to screen for, identify, select, and synthesize amphiphilic mitochondrially targeted antioxidant compds., and compns., dosage forms, and methods reliant on these compds. The compds. are all mitoquinone derivs., being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivs. The compds., compns., dosage forms and

methods are useful in e.g. the treatment of diseases or conditions associated with oxidative stress.


IT 444890-41-9 794485-93-1 794485-94-2

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)


RN 444890-41-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)




RN 794485-93-1 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl- (CA INDEX NAME)



RN 794485-94-2 CAPLUS

CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl- (CA INDEX NAME)



IT 845959-57-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

10/568,655


07/27/2008

RN 845959-57-1 CAPLUS
CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




● Br⁻

IT 764723-90-2P 764723-92-4P 845959-58-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(mitoquinone derivative preparation for mitochondrially targeted antioxidant)
RN 764723-90-2 CAPLUS
CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 764723-92-4 CAPLUS
CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




RN 845959-58-2 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 794485-93-1


CMF C30 H30 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S




IT 794485-95-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 794485-95-3 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:182677 CAPLUS
 DOCUMENT NUMBER: 142:254661
 TITLE: Mitoquinone derivatives used as mitochondrially targeted antioxidants, and preparation thereof
 INVENTOR(S): Taylor, Kenneth Martin; Smith, Robin
 PATENT ASSIGNEE(S): Antipodean Biotechnology Limited, N. Z.
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------|------------------|----------|
| WO 2005019232 | A1 | 20050303 | WO 2004-NZ196 | 20040823 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003204144 | A1 | 20030612 | AU 2003-204144 | 20030512 |
| AU 2003204144 | B2 | 20070301 | | |
| AU 2004266988 | A1 | 20050303 | AU 2004-266988 | 20040823 |
| CA 2536546 | A1 | 20050303 | CA 2004-2536546 | 20040823 |
| EP 1664069 | A1 | 20060607 | EP 2004-775122 | 20040823 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1839142 | A | 20060927 | CN 2004-80024155 | 20040823 |
| BR 2004013742 | A | 20061024 | BR 2004-13742 | 20040823 |
| JP 2007503387 | T | 20070222 | JP 2006-523805 | 20040823 |
| US 20060229278 | A1 | 20061012 | US 2006-355518 | 20060215 |
| MX 2006PA02114 | A | 20061207 | MX 2006-PA2114 | 20060222 |
| NO 2006000977 | A | 20060519 | NO 2006-977 | 20060228 |
| US 20080161267 | A1 | 20080703 | US 2006-568655 | 20060831 |
| PRIORITY APPLN. INFO.: | | NZ 2003-527800 | A 20030822 | |
| | | NZ 2003-529153 | A 20031023 | |

| | | | |
|----|-------------|----|----------|
| NZ | 2004-533556 | A | 20040614 |
| AU | 1999-16965 | A3 | 19981125 |
| NZ | 1998-329255 | A | 19981125 |
| WO | 1998-NZ173 | A2 | 19981125 |
| US | 2000-577877 | A1 | 20000525 |
| US | 2001-968838 | B1 | 20011003 |
| US | 2002-272914 | B1 | 20021018 |
| US | 2003-722542 | B1 | 20031128 |
| WO | 2004-NZ196 | W | 20040823 |
| US | 2005-172916 | A2 | 20050705 |

OTHER SOURCE(S): CASREACT 142:254661; MARPAT 142:254661

AB The invention discloses pharmaceutically acceptable amphiphilic antioxidant compds., compns., and dosage forms comprising these compds., and methods and uses reliant on these compds. The compds. are all mitoquinone derivs., being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivs. The compds., compns., dosage forms, uses, and methods are useful in e.g. the treatment of diseases or conditions associated with oxidative stress.

IT 845959-50-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)


RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 444890-41-9


CMF C37 H44 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S



IT 845959-59-3P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(mitoquinone derivative preparation for mitochondrially targeted antioxidant)


RN 845959-59-3 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 444890-41-9

CMF C37 H44 O4 P




CM 2

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




IT 764723-90-2P 764723-92-4P 845959-58-2P
845959-60-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 764723-90-2 CAPLUS


CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 764723-92-4 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻


RN 845959-58-2 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 794485-93-1


CMF C30 H30 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S




RN 845959-60-6 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (4:1) (9CI) (CA INDEX NAME)

CM 1

CRN 444890-41-9

CMF C37 H44 O4 P




CM 2

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 845959-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 845959-56-0 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P




CM 4

CRN 16053-58-0
 CMF C H3 O3 S




IT 444890-41-9 845959-51-5 845959-52-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (mitoquinone derivative preparation for mitochondrially targeted
 antioxidant)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



RN 845959-51-5 CAPLUS
 CN β-Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 2


10/568, 655

07/27/2008

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 845959-52-6 CAPLUS


CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 4

CRN 16053-58-0
CMF C H3 O3 S




IT 336184-91-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

BN 336184-91-9 CAPLUS

RN 33814-91-9 CASLCS
CN Phosphonyl, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




● Br⁻

IT 845959-57-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

antioxidant)
BN 845959-57-1 CAPTUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:710408 CAPLUS
 DOCUMENT NUMBER: 141:236523
 TITLE: Supplementation of Endothelial Cells with Mitochondria-targeted Antioxidants Inhibit Peroxide-induced Mitochondrial Iron Uptake, Oxidative Damage, and Apoptosis
 AUTHOR(S): Dhanasekaran, Anuradha; Kotamraju, Srigiridhar; Kalivendi, Shashi V.; Matsunaga, Toshiyuki; Shang, Tiesong; Keszler, Agnes; Joseph, Joy; Kalyanaraman, B.
 CORPORATE SOURCE: Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
 SOURCE: Journal of Biological Chemistry (2004), 279(36), 37575-37587
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The mitochondria-targeted drugs mitoquinone (Mito-Q) and mitovitamin E (MitoVit-E) are a new class of antioxidants containing the triphenylphosphonium cation moiety that facilitates drug accumulation in mitochondria. In this study, Mito-Q (ubiquinone attached to a triphenylphosphonium cation) and MitoVit-E (vitamin E attached to a triphenylphosphonium cation) were used. The aim of this study was to test the hypothesis that mitochondria-targeted antioxidants inhibit peroxide-induced oxidative stress and apoptosis in bovine aortic endothelial cells (BAEC) through enhanced scavenging of mitochondrial reactive oxygen species, thereby blocking reactive oxygen species-induced transferrin receptor (TfR)-mediated iron uptake into mitochondria. Glucose/glucose oxidase-induced oxidative stress in BAECs was monitored by oxidation of dichlorodihydrofluorescein that was catalyzed by both intracellular H₂O₂ and transferrin iron transported into cells. Pretreatment of BAECs with Mito-Q (1 μM) and MitoVit-E (1 μM) but not untargeted antioxidants (e.g. vitamin E) significantly abrogated H₂O₂- and lipid peroxide-induced 2',7'-dichlorofluorescein fluorescence and protein oxidation. Mitochondria-targeted antioxidants inhibit cytochrome c release, caspase-3 activation, and DNA fragmentation. Mito-Q and MitoVit-E inhibited H₂O₂- and lipid peroxide-induced inactivation of

complex I and aconitase, TfR overexpression, and mitochondrial uptake of 55Fe, while restoring the mitochondrial membrane potential and proteasomal activity. The authors conclude that Mito-Q or MitoVit-E supplementation of endothelial cells mitigates peroxide-mediated oxidant stress and maintains proteasomal function, resulting in the overall inhibition of TfR-dependent iron uptake and apoptosis.


IT 336184-91-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis)

RN 336184-91-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:601038 CAPLUS

DOCUMENT NUMBER: 141:290668

TITLE: Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant

AUTHOR(S): Asin-Cayuela, Jordi; Manas, Abdul-Rahman B.; James, Andrew M.; Smith, Robin A. J.; Murphy, Michael P.

CORPORATE SOURCE: Wellcome Trust/MRC Building, Medical Research Council Dunn Human Nutrition Unit, Cambridge, CB2 2XY, UK

SOURCE: FEBS Letters (2004), 571(1-3), 9-16
CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:290668

AB The mitochondria-targeted antioxidant MitoQ comprises a ubiquinol moiety covalently attached through an aliphatic carbon chain to the lipophilic triphenylphosphonium cation. This cation drives the membrane potential-dependent accumulation of MitoQ into mitochondria, enabling the ubiquinol antioxidant to prevent mitochondrial oxidative damage far more effectively than untargeted antioxidants. We sought to fine-tune the hydrophobicity of MitoQ so as to control the extent of its membrane binding and penetration into the phospholipid bilayer, and thereby regulate its partitioning between the membrane and aqueous phases within


mitochondria and cells. To do this, MitoQ variants with 3, 5, 10 and 15 carbon aliphatic chains were synthesized. These mols. had a wide range of hydrophobicities with octan-1-ol/phosphate buffered saline partition coeffs. from 2.8 to 20,000. All MitoQ variants were accumulated into mitochondria driven by the membrane potential, but their binding to phospholipid bilayers varied from negligible for MitoQ3 to essentially total for MitoQ15. Despite the span of hydrophobicities, all MitoQ variants were effective antioxidants. Therefore, it is possible to fine-tune the degree of membrane association of MitoQ and other mitochondria targeted compds., without losing antioxidant efficacy. This indicates how the uptake and distribution of mitochondria-targeted compds. within mitochondria and cells can be controlled, thereby facilitating investigations of mitochondrial oxidative damage.

IT 764723-90-2P 764723-92-4P 845959-57-1P

RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of MitoQ variants for fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant)

RN 764723-90-2 CAPLUS


CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 764723-92-4 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




● Br⁻

RN 845959-57-1 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-

yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

IT 845959-58-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of MitoQ variants for fine-tuning the hydrophobicity of a
mitochondria-targeted antioxidant)


RN 845959-58-2 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-
yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 794485-93-1


CMF C₃₀ H₃₀ O₄ P



CM 2

CRN 16053-58-0

CMF C H₃ O₃ S



REFERENCE COUNT:

40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:434607 CAPLUS
 DOCUMENT NUMBER: 141:49659
 TITLE: Mitochondria-derived reactive oxygen species mediate blue light-induced death of retinal pigment epithelial cells
 AUTHOR(S): King, Ayala; Gottlieb, Eyal; Brooks, David G.; Murphy, Michael P.; Dunaief, Joshua L.
 CORPORATE SOURCE: F.M. Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA, USA
 SOURCE: Photochemistry and Photobiology (2004), 79(5), 470-475
 CODEN: PHCBAP; ISSN: 0031-8655
 PUBLISHER: American Society for Photobiology
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Throughout the lifetime of an individual, light is focused onto the retina. The resulting photooxidative stress can cause acute or chronic retinal damage. The pathogenesis of age-related macular degeneration (AMD), the leading cause of legal blindness in the developed world, involves oxidative stress and death of the retinal pigment epithelium (RPE) followed by death of the overlying photoreceptors. Evidence suggests that damage due to exposure to light plays a role in AMD and other age-related eye diseases. In this work a system for light-induced damage and death of the RPE, based on the human ARPE-19 cell line, was used. Induction of mitochondria-derived reactive oxygen species (ROS) is shown to play a critical role in the death of cells exposed to short-wavelength blue light (425 ± 20 nm). ROS and cell death are blocked either by inhibiting the mitochondrial electron transport chain or by mitochondria-specific antioxidants. These results show that mitochondria are an important source of toxic oxygen radicals in blue light-exposed RPE cells and may indicate new approaches for treating AMD using mitochondria-targeted antioxidants.

IT 336184-91-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitochondria-derived ROS mediate blue light-induced death of retinal pigment epithelium)

RN 336184-91-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻


REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:826167 CAPLUS
 DOCUMENT NUMBER: 140:53354
 TITLE: Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants
 AUTHOR(S): Jauslin, Matthias L.; Meier, Thomas; Smith, Robin A. J.; Murphy, Michael P.
 CORPORATE SOURCE: MyoContract Ltd., Liestal, CH-4410, Switz.
 SOURCE: FASEB Journal (2003), 17(13), 1972-1974,
 10.1096/fj.03-0240fje
 CODEN: FAJOEC; ISSN: 0892-6638
 PUBLISHER: Federation of American Societies for Experimental Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Friedreich Ataxia (FRDA), the most common inherited ataxia, arises from defective expression of the mitochondrial protein frataxin, which leads to increased mitochondrial oxidative damage. Therefore, antioxidants targeted to mitochondria should be particularly effective at slowing disease progression. To test this hypothesis, we compared the efficacy of mitochondria-targeted and untargeted antioxidants derived from coenzyme Q10 and from vitamin E at preventing cell death due to endogenous oxidative stress in cultured fibroblasts from FRDA patients in which glutathione synthesis was blocked. The mitochondria-targeted antioxidant MitoQ was several hundredfold more potent than the untargeted analog idebenone. The mitochondria-targeted antioxidant MitoVit E was 350-fold more potent than the water soluble analog Trolox. This is the first demonstration that mitochondria-targeted antioxidants prevent cell death that arises in response to endogenous oxidative damage. Targeted antioxidants may have therapeutic potential in FRDA and in other disorders involving mitochondrial oxidative damage.

IT 444890-41-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants)

RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

10/568,655

07/27/2008

ACCESSION NUMBER: 2003:426934 CAPLUS
DOCUMENT NUMBER: 140:74526
TITLE: MitoQ counteracts telomere shortening and elongates lifespan of fibroblasts under mild oxidative stress
AUTHOR(S): Saretzki, Gabriele; Murphy, Michael P.; von Zglinicki, Thomas
CORPORATE SOURCE: Gerontology, Institute of Aging and Health, Newcastle University, Newcastle upon Tyne, NE4 6BE, UK
SOURCE: Aging Cell (2003), 2(2), 141-143
CODEN: ACGECQ; ISSN: 1474-9718
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effect of the mitochondria-specific antioxidant mitoQ [10-(6'-ubiquinonyl) decyltriphenylphosphonium bromide] in human fibroblasts under mild stress conditions was investigated. Treatment of MRC-5 fibroblasts with mitoQ under these conditions significantly decreased the cellular peroxide content and elongated the replicative lifespan. MitoQ treatment completely prevented the rise in telomere shortening rate due to hyperoxia and instead gave a negligible rate of telomere shortening.
IT 336184-91-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MitoQ counteracts telomere shortening and elongates lifespan of human fibroblasts under mild oxidative stress)
RN 336184-91-9 CAPLUS
CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:154438 CAPLUS
DOCUMENT NUMBER: 138:187926
TITLE: Preparation of triphenylphosphonium quinols and quinones
INVENTOR(S): Smith, Robin; Murphy, Michael Patrick
PATENT ASSIGNEE(S): Antipodean Biotechnology Limited, N. Z.
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|---------------------|-------------------|-----------------|------------|
| WO 2003016323 | A1 | 20030227 | WO 2002-NZ154 | 20020812 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| NZ 513547 | A | 20020927 | NZ 2001-513547 | 20010813 |
| AU 2002326242 | A1 | 20030303 | AU 2002-326242 | 20020812 |
| EP 1423396 | A1 | 20040602 | EP 2002-760924 | 20020812 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| US 20050043553 | A1 | 20050224 | US 2004-486797 | 20041001 |
| US 7179928 | B2 | 20070220 | | |
| PRIORITY APPLN. INFO.: | | | NZ 2001-513547 | A 20010813 |
| | | | WO 2002-NZ154 | W 20020812 |
| OTHER SOURCE(S): | CASPEACT 128-187926 | MARPAT 128-187926 | | |

OTHER SOURCE(S): CASREACT 138:187926; MARPAT 138:187926
GT




AB Triphenylphosphonium quinols and quinones [e.g., I and II, resp.; wherein n = integer from 6 to 40] were prepared. For example, Idebenone is reacted with PPh₃ and PPh₃•HBr to give 57% MitoQuinol I Br⁻ (n = 10), which is purified and oxidized with H₂O₂/pyridine to give 77% MitoQuinone II Br⁻ (n = 10).

IT 336184-91-9P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of triphenylphosphonium quinols and quinones)
RN: 226194-91-8 CMLWS

RN 336184-91-9 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




● Br⁻

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:411988 CAPLUS
 DOCUMENT NUMBER: 137:139797
 TITLE: Prevention of mitochondrial oxidative damage using targeted antioxidants
 AUTHOR(S): Kelso, Geoffrey F.; Porteous, Carolyn M.; Hughes, Gillian; Ledgerwood, Elizabeth C.; Gane, Alison M.; Smith, Robin A. J.; Murphy, Michael P.
 CORPORATE SOURCE: Departments of Chemistry, University of Otago, Dunedin, N. Z.
 SOURCE: Annals of the New York Academy of Sciences (2002), 959(Increasing Health Life Span), 263-274
 CODEN: ANYAA9; ISSN: 0077-8923
 PUBLISHER: New York Academy of Sciences
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two mitochondria-targeted antioxidants that can selectively block mitochondrial oxidative damage and prevent some types of cell death were developed. They were ubiquinone and tocopherol derivs. targeted to mitochondria by covalent attachment to the lipophilic triphenylphosphonium cation. The effects of the 2 derivs. and nontargeted ubiquinone and tocopherol were examined in vitro in rat liver and beef heart mitochondrial preps. and in Jurkat human T lymphocyte cell line and in vivo in female Swiss Webster mice. Because of the large mitochondrial membrane potential, these cations can accumulated within mitochondria inside the cells, where the antioxidant moiety prevented lipid peroxidn. and protected the mitochondria from oxidative damage. The mitochondrially localized ubiquinone derivative also protected mammalian cells from hydrogen peroxide-induced apoptosis while the nontargeted ubiquinone analog was ineffective against cell apoptosis. When fed to mice, the 2 derivs. accumulated in the brain, heart, and liver. These mitochondria-targeted antioxidants may help in investigations of the role of mitochondrial oxidative damage in animal models of aging.
 IT 444890-41-9
 RL: BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (dietary ubiquinone and tocopherol targeted antioxidant derivs. use in prevention of mitochondrial oxidative damage in vitro and in mice)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-

yl)decyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:137933 CAPLUS

DOCUMENT NUMBER: 134:322127

TITLE: Selective targeting of a redox-active ubiquinone to mitochondria within cells. Antioxidant and antiapoptotic properties

AUTHOR(S): Kelso, Geoffrey F.; Porteous, Carolyn M.; Coulter, Carolyn V.; Hughes, Gillian; Porteous, William K.; Ledgerwood, Elizabeth C.; Smith, Robin A. J.; Murphy, Michael P.

CORPORATE SOURCE: Department of Chemistry, University of Otago, Dunedin,
N. Z.

SOURCE: Journal of Biological Chemistry (2001), 276(7), 4588-4596

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:322127

AB With the recognition of the central role of mitochondria in apoptosis, there is a need to develop specific tools to manipulate mitochondrial function within cells. Here we report on the development of a novel antioxidant that selectively blocks mitochondrial oxidative damage, enabling the roles of mitochondrial oxidative stress in different types of cell death to be inferred. This antioxidant, named mitoQ, is a ubiquinone derivative targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium cation through an aliphatic carbon chain. Due to the large mitochondrial membrane potential, the cation was accumulated within mitochondria inside cells, where the ubiquinone moiety inserted into the lipid bilayer and was reduced by the respiratory chain. The ubiquinol derivative thus formed was an effective antioxidant that prevented lipid peroxidation and protected mitochondria from oxidative damage. After detoxifying the reactive oxygen species peroxynitrite, the ubiquinol moiety was regenerated by the respiratory chain enabling its antioxidant activity to be recycled. In cell culture studies, the mitochondrially localized antioxidant protected mammalian cells from hydrogen peroxide-induced apoptosis but not from apoptosis induced by staurosporine or tumor necrosis factor- α . This was compared with untargeted ubiquinone analogs, which were ineffective in preventing apoptosis. These results suggest that mitochondrial oxidative stress may be a critical step in apoptosis induced by hydrogen peroxide but not for apoptosis induced by


staurosporine or tumor necrosis factor- α . We have shown that selectively manipulating mitochondrial antioxidant status with targeted and recyclable antioxidants is a feasible approach to investigate the role of mitochondrial oxidative damage in apoptotic cell death. This approach will have further applications in investigating mitochondrial dysfunction in a range of exptl. models.

IT 336184-91-9P 336184-92-0P
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(novel redox-active ubiquinone mitoQ displays antioxidant and antiapoptotic properties in mitochondria)

RN 336184-91-9 CAPLUS


CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 336184-92-0 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide, labeled with tritium (9CI) (CA INDEX NAME)



● Br⁻

REFERENCE COUNT:

49

THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> S L3 AND IDEBENOL
 3 IDEBENOL
 L4 2 L3 AND IDEBENOL

=> D L4 IBIB ABS HITSTR 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:182678 CAPLUS
 DOCUMENT NUMBER: 142:254662
 TITLE: Mitoquinone derivatives used as mitochondrially targeted antioxidants, and preparation thereof
 INVENTOR(S): Murphy, Michael Patrick; Smith, Robin
 PATENT ASSIGNEE(S): Antipodean Biotechnology Limited, N. Z.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|--|---|
| WO 2005019233 | A1 | 20050303 | WO 2004-NZ197 | 20040823 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003204144 | A1 | 20030612 | AU 2003-204144 | 20030512 |
| AU 2003204144 | B2 | 20070301 | | |
| US 20070238709 | A1 | 20071011 | US 2007-568654 NZ 2003-527800 NZ 2003-529153 NZ 2004-533555 AU 1999-16965 NZ 1998-329255 WO 2004-NZ197 | 20070222 A 20030822 A 20031023 A 20040614 A3 19981125 A 19981125 W 20040823 |
| PRIORITY APPLN. INFO.: | | | | |

OTHER SOURCE(S): CASREACT 142:254662; MARPAT 142:254662
 AB This invention discloses methods to screen for, identify, select, and synthesize amphiphilic mitochondrially targeted antioxidant compds., and compns., dosage forms, and methods reliant on these compds. The compds. are all mitoquinone derivs., being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivs. The compds., compns., dosage forms and methods are useful in e.g. the treatment of diseases or conditions associated with oxidative stress.
 IT 444890-41-9 794485-93-1 794485-94-2
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mitoquinone derivative preparation for mitochondrially targeted antioxidant)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)




RN 794485-93-1 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl- (CA INDEX NAME)



RN 794485-94-2 CAPLUS

CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl- (CA INDEX NAME)




IT 845959-57-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 845959-57-1 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻


IT 764723-90-2P 764723-92-4P 845959-58-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 764723-90-2 CAPLUS


CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 764723-92-4 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)




● Br⁻

10/568, 655 07/27/2008

RN 845959-58-2 CAPLUS
CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 794485-93-1
CMF C30 H30 O4 P




CM 2

CRN 16053-58-0
CMF C H3 O3 S



IT 794485-95-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(mitoquinone derivative preparation for mitochondrially targeted
antioxidant)
RN 794485-95-3 CAPLUS
CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:182677 CAPLUS
 DOCUMENT NUMBER: 142:254661
 TITLE: Mitoquinone derivatives used as mitochondrially targeted antioxidants, and preparation thereof
 INVENTOR(S): Taylor, Kenneth Martin; Smith, Robin
 PATENT ASSIGNEE(S): Antipodean Biotechnology Limited, N. Z.
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-------------|
| WO 2005019232 | A1 | 20050303 | WO 2004-NZ196 | 20040823 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2003204144 | A1 | 20030612 | AU 2003-204144 | 20030512 |
| AU 2003204144 | B2 | 20070301 | | |
| AU 2004266988 | A1 | 20050303 | AU 2004-266988 | 20040823 |
| CA 2536546 | A1 | 20050303 | CA 2004-2536546 | 20040823 |
| EP 1664069 | A1 | 20060607 | EP 2004-775122 | 20040823 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1839142 | A | 20060927 | CN 2004-80024155 | 20040823 |
| BR 2004013742 | A | 20061024 | BR 2004-13742 | 20040823 |
| JP 2007503387 | T | 20070222 | JP 2006-523805 | 20040823 |
| US 20060229278 | A1 | 20061012 | US 2006-355518 | 20060215 |
| MX 2006PA02114 | A | 20061207 | MX 2006-PA2114 | 20060222 |
| NO 2006000977 | A | 20060519 | NO 2006-977 | 20060228 |
| US 20080161267 | A1 | 20080703 | US 2006-568655 | 20060831 |
| PRIORITY APPLN. INFO.: | | | NZ 2003-527800 | A 20030822 |
| | | | NZ 2003-529153 | A 20031023 |
| | | | NZ 2004-533556 | A 20040614 |
| | | | AU 1999-16965 | A3 19981125 |
| | | | NZ 1998-329255 | A 19981125 |
| | | | WO 1998-NZ173 | A2 19981125 |
| | | | US 2000-577877 | A1 20000525 |
| | | | US 2001-968838 | B1 20011003 |
| | | | US 2002-272914 | B1 20021018 |
| | | | US 2003-722542 | B1 20031128 |
| | | | WO 2004-NZ196 | W 20040823 |
| | | | US 2005-172916 | A2 20050705 |

OTHER SOURCE(S): CASREACT 142:254661; MARPAT 142:254661

AB The invention discloses pharmaceutically acceptable amphiphilic antioxidant compds., compns., and dosage forms comprising these compds., and methods and uses reliant on these compds. The compds. are all

mitoquinone derivs., being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivs. The compds., compns., dosage forms, uses, and methods are useful in e.g. the treatment of diseases or conditions associated with oxidative stress.

IT 845959-50-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)


RN 845959-50-4 CAPLUS

CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 444890-41-9


CMF C37 H44 O4 P



CM 2

CRN 16053-58-0

CMF C H3 O3 S



IT 845959-59-3P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 845959-59-3 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 444890-41-9

10/568, 655

07/27/2008

CMF C37 H44 O4 P




CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 764723-90-2P 764723-92-4P 845959-58-2P


845959-60-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)


RN 764723-90-2 CAPLUS

CN Phosphonium, [5-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentyl]triphenyl-, iodide (1:1) (CA INDEX NAME)

● I⁻

RN 764723-92-4 CAPLUS

CN Phosphonium, [15-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)pentadecyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻


RN 845959-58-2 CAPLUS

CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 794485-93-1


CMF C30 H30 O4 P



CM 2

CRN 16053-58-0
CMF C H3 O3 SRN 845959-60-6 CAPLUS
CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (4:1) (9CI) (CA INDEX NAME)


CM 1

CRN 444890-41-9
CMF C37 H44 O4 P

CM 2

CRN 7585-39-9
CMF C42 H70 O35**Absolute stereochemistry.**

PAGE 1-A



PAGE 2-A



IT 845959-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(mitoquinone derivative preparation for mitochondrially targeted antioxidant)

RN 845959-56-0 CAPLUS

CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P




CM 4

CRN 16053-58-0
 CMF C H3 O3 S




IT 444890-41-9 845959-51-5 845959-52-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (mitoquinone derivative preparation for mitochondrially targeted
 antioxidant)
 RN 444890-41-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl- (CA INDEX NAME)



RN 845959-51-5 CAPLUS
 CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 444890-41-9
 CMF C37 H44 O4 P



CM 2


10/568, 655

07/27/2008

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 845959-52-6 CAPLUS


CN β -Cyclodextrin, compd. with [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 845959-50-4
 CMF C37 H44 O4 P . C H3 O3 S


CM 3

CRN 444890-41-9
 CMF C37 H44 O4 P




CM 4

CRN 16053-58-0
 CMF C H3 O3 S




IT 336184-91-9

RL: RCT (Reactant); RACT (Reactant or reagent)
 (mitoquinone derivative preparation for mitochondrially targeted antioxidant)
 RN 336184-91-9 CAPLUS
 CN Phosphonium, [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenyl-, bromide (1:1) (CA INDEX NAME)

● Br⁻

IT 845959-57-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (mitoquinone derivative preparation for mitochondrially targeted antioxidant)
 RN 845959-57-1 CAPLUS
 CN Phosphonium, [3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)propyl]triphenyl-, bromide (1:1) (CA INDEX NAME)



● Br⁻

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

| | | |
|--|------------|---------|
| => FIL STNGUIDE | SINCE FILE | TOTAL |
| COST IN U.S. DOLLARS | ENTRY | SESSION |
| FULL ESTIMATED COST | 209.05 | 387.62 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY | SESSION |
| | -29.60 | -29.60 |

FILE 'STNGUIDE' ENTERED AT 13:15:25 ON 27 JUL 2008
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Jul 18, 2008 (20080718/UP).

=>

---Logging off of STN---

=>
 Executing the logoff script...

=> LOG Y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | ENTRY | SESSION |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY | SESSION |
| | 0.00 | -29.60 |

STN INTERNATIONAL LOGOFF AT 13:15:51 ON 27 JUL 2008